

Supplementary Table 1. Treatment outcomes of antiviral therapy in entire population and subgroups with and without hepatic steatosis

Variables	All patients (n=334)	Patients with hepatic steatosis (n=146, 43.7%)	Patients without hepatic steatosis (n=188, 56.3%)
HBeAg loss*			
n (HBeAg-positive)	172	80	92
1-year	9 (5.2)	4 (5.0)	5 (5.4)
3-years	32 (18.6)	10 (12.5)	22 (23.9)
5-years	37 (21.5)	11 (13.8)	26 (28.3)
Complete virological response			
1-year	218 (65.3)	88 (60.3)	130 (69.1)
3-years	300 (89.8)	126 (86.3)	174 (92.6)
5-years	303 (90.7)	127 (87.0)	176 (93.6)
Hepatocellular carcinoma			
1-year	6 (1.8)	1 (0.7)	5 (2.7)
3-years	16 (4.8)	5 (3.4)	11 (5.9)
5-years	25 (7.5)	8 (5.5)	17 (9.0)

Variables are expressed as n or n (%).

HBeAg, hepatitis B e antigen.

*The rate of HBeAg loss was calculated among HBeAg-positive patients.